News

The oral nucleoside TAS-102 (Lonsurf) has been approved by the FDA for patients with advanced colorectal cancer (CRC) who are not responding to other treatments.

Carfilzomib (Kyprolis) in combination with dexamethasone, was recently granted a priority review designation by the FDA for patients who have relapsed multiple myeloma, following prior treatment with at least one therapy.

Oncoviruses have been implicated to cause 17.8% of human cancers.

The bovine leukemia virus, or BLV, which is transmitted between cattle herds may play a key role in the development of breast cancer.

Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.

AbbVie has submitted a supplemental new drug application for its BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia (CLL) who are over the age of 65.

The PD-1 inhibitor immunotherapy Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

An experimental immunotherapy for human papillomavirus-, or HPV-, related throat cancers, which is driven by the Listeria bacteria (that wreaks havoc when ingested), may now move forward.

Abstracts highlighting the latest clinical data on lenvatinib are expected at the 2015 European Cancer Congress in Vienna, Austria.

The attenuated vaccinia virus, GL-ONC1, demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy in patients who have locoregionally advanced head and neck carcinoma (LA-HNC).

A novel trap and detection system in preclinical trials may leverage advances in the detection of circulating tumor cells (CTCs) to find and stop metastatic cancer cells from spreading.

Ixazomib (MLN9708), an oral proteasome inhibitor, was recently granted a priority review designation by the FDA, in combination with lenalidomide and dexamethasone for the treatment of patients who have relapsed and/or refractory multiple myeloma.

Administering 6 cycles of docetaxel at the beginning of androgen-deprivation therapy (ADT) to patients with metastatic, hormone-sensitive prostate cancer (mHSPC) resulted in a significantly longer overall survival (OS) than ADT alone.

A paper published in the Journal of Clinical Oncology, authored by Tosoian et al, reports on the long-term outcomes of prospective active surveillance (AS) of patients with favorable-risk prostate cancer.

Radium-223 dichloride (Xofigo) has shown a significant survival advantage in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases, and a multidisciplinary approach to treatment has become more widely practiced in community clinics.

The FDA recently granted alectinib a priority review designation for patients who have ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) and progressed or are intolerant to crizotinib (Xalkori).

A novel immunotherapy, EGEN-001, combined with pegylated liposomal doxorubicin (PLD) has demonstrated clinical benefit in recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients.

The fully human PD-L1 IgG1 antibody, avelumab, demonstrated clinical activity in patients who have previously treated, recurrent/refractory (R/R) ovarian cancer.

Results of the CHORUS trial confirm the noninferiority of primary chemotherapy followed by surgery versus primary surgery and then chemotherapy, and show that performing chemotherapy first is associated with less morbidity and mortality in patients with newly diagnosed, advanced ovarian cancer.

Daratumumab was recently assigned a priority review designation by the FDA as a treatment for patients who have multiple myeloma.

The phase I results of RRx-001, which has multiple epigenetic targets, have been published in Lancet Oncology. The drug is of interest because epigenetic alterations are associated with resistance to chemotherapy.

Zarxio (filgrastim-sndz), the first FDA-approved biosimilar, is now available for patients in the United States, after a series of court decisions and lawsuits.

The standard of care for lung cancers has been dramatically transformed by the growing availability of molecular diagnostics and genetic testing, and by targeted therapies that specifically inhibit a number of well-established oncogenic drivers.

US Veterans, including former Air Force personnel who participated in Operation Ranch Hand, have a 2.4-fold increased risk of multiple myeloma’s precursor state, MGUS,

Nivolumab (Opdivo) was given a priority review designation by the FDA for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC).

A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.

Rolapitant (Varubi) was recently approved by the FDA for use in combination with other antiemetic agents, in order to prevent delayed CINV from initial and repeat chemotherapy regiments, including highly emetogenic chemotherapy.

Elotuzumab (Empliciti) was recently granted a priority review by the FDA for use in combination therapy in patients who have multiple myeloma, following the failure of one or more prior therapies.

A priority review designation was recently assigned by the FDA to the intravesical immunotherapy MCNA as a treatment for patients who have high-risk non-muscle invasive bladder cancer, following first-line bacillus Calmette-Guérin (BCG) therapy.

A novel basket trial has reported results on the treatment of vemurafenib in variety of nonmelanoma cancers with BRAF V600 mutation.